bioAffinity Technologies

bioAffinity Technologies Addressing the need for noninvasive diagnosis of early-stage cancer and targeted cancer treatment. www.cypathlung.com

Our flagship product, CyPath® Lung, is a noninvasive early lung cancer diagnostic.

07/03/2026

Imaging can identify pulmonary nodules, but clinicians often need more to go on to determine the the appropriate next steps.

The CyPath® Lung test gives you more than imaging to go on. With results indicating “likely” or “unlikely” malignancy, CyPath® Lung provides actionable, noninvasive diagnostic insight to support clinicians as they evaluate indeterminate pulmonary nodules and guide next-step decisions.

This added clarity can help guide discussions about surveillance or intervention while supporting patient confidence.

Learn more: https://www.cypathlung.com/

Thank you to everyone who connected with us at the 2026 RNA Therapeutics Symposium.Dr. William Bauta, Chief Science Offi...
07/01/2026

Thank you to everyone who connected with us at the 2026 RNA Therapeutics Symposium.

Dr. William Bauta, Chief Science Officer, and Dr. David Elzi, Vice President of Product Development, presented bioAffinity Technologies' latest preclinical research exploring a novel siRNA approach targeting squamous and basal skin cancer.

We appreciate everyone who stopped by our poster to discuss our research. It was a pleasure exchanging ideas with researchers and industry colleagues while learning about new developments across the RNA therapeutics field.

Today is your chance to make an even greater impact.As part of the American Lung Association's "Breathe New Life Into Re...
06/30/2026

Today is your chance to make an even greater impact.

As part of the American Lung Association's "Breathe New Life Into Research" campaign, bioAffinity Technologies is providing a 5X match for qualifying donations today to support research focused on lung cancer, COPD, asthma and other lung diseases.

bioAffinity Technologies is proud to support the American Lung Association and its commitment to advancing lung health through research.

🫁 Donate today: https://bit.ly/4v8jQeR

06/26/2026

When pulmonary nodules are discovered, clinicians and patients both want timely answers.

CyPath® Lung can accelerate diagnosis with an easy-to-use at-home test that uses flow cytometry + AI to analyze the patient’s lung microenvironment.

CyPath® Lung helps clinicians assess malignancy risk by providing actionable results that support informed decisions about next steps in patient care.

Learn more: https://www.cypathlung.com/

Thanks to for its recent blog post on the common myths about lung cancer. See the blog at https://lnkd.in/gBzFxZKD.As w...
06/25/2026

Thanks to for its recent blog post on the common myths about lung cancer. See the blog at https://lnkd.in/gBzFxZKD.

As we work to dispel myths about lung cancer, we must also continue expanding access to tools that support earlier detection and more informed clinical decisions.

CyPath® Lung is a noninvasive test designed to help physicians assess the risk of lung cancer in high-risk patients with indeterminate pulmonary nodules. By analyzing sputum samples with advanced flow cytometry and AI, CyPath® Lung provides valuable information to complement imaging and help guide patient management. Visit www.cypathlung.com for more info.

Basal cell and squamous cell carcinoma are among the most common cancers diagnosed in the United States, with an estimat...
06/24/2026

Basal cell and squamous cell carcinoma are among the most common cancers diagnosed in the United States, with an estimated 5.4 million cases identified each year.

Today at the 2026 RNA Therapeutics Symposium, bioAffinity Technologies presented positive preclinical findings for a siRNA-based therapy targeting these common skin cancers.

The newly released findings represent an encouraging step toward developing less-invasive treatments, highlighting in vitro research evaluating targeting specific cell surface receptors. In the study, squamous and basal skin cancer cell proliferation was significantly impaired, while non-cancerous skin cells were unaffected.

Read more: bit.ly/4aPlzgX

A new modeling study found that screening eligibility based on years smoked may perform as well as current pack-year cri...
06/24/2026

A new modeling study found that screening eligibility based on years smoked may perform as well as current pack-year criteria while potentially reducing disparities and simplifying implementation.

As more high-risk individuals are identified through screening programs, tools like CyPath® Lung (www.cypathlung.com) can help physicians assess lung cancer risk in patients with indeterminate pulmonary nodules using a simple, noninvasive sputum sample.

Read the study at https://bit.ly/4akCjwq and join the conversation about the future of lung cancer risk assessment.

For more than 120 years, the American Lung Association has supported research that advances lung health and improves liv...
06/23/2026

For more than 120 years, the American Lung Association has supported research that advances lung health and improves lives.

Today, the organization is funding 130 research projects and building on a legacy that includes more than 1,900 funded research initiatives since 1915.

As proud sponsors of the American Lung Association, we're honored to support the "Breathe New Life Into Research" campaign with 3x matching for donations through June 30.

Learn more and make a donation: https://bit.ly/4uHzJbh

Attending the 2026 RNA Therapeutics (RNATx) Symposium, June 24-26 in Worcester, MA?bioAffinity Technologies reports posi...
06/22/2026

Attending the 2026 RNA Therapeutics (RNATx) Symposium, June 24-26 in Worcester, MA?

bioAffinity Technologies reports positive preclinical findings showing its proprietary gene-silencing technology kills squamous skin cancer cells while leaving healthy cells unharmed. The research supports the company's R&D on potential topical therapeutic approaches for squamous cell and basal cell carcinoma.

The findings will be presented at the symposium by David J. Elzi, PhD, bioAffinity Technologies’ Vice President of Product Development.

We look forward to joining researchers, biotech/pharma, clinicians and industry focused on RNA therapeutics, oligonucleotides, mRNA, siRNA, gene editing and translational medicine.

Learn more: https://bit.ly/4aPlzgX RNA Therapeutics Institute

🫁 SAB-hosted webinar featuring CyPath Lung is now posted at https://bit.ly/43N4fW1"Navigating Lower Cancer-Risk Nodules ...
06/19/2026

🫁 SAB-hosted webinar featuring CyPath Lung is now posted at https://bit.ly/43N4fW1
"Navigating Lower Cancer-Risk Nodules in High-Risk Patients With Noninvasive CyPath® Lung Testing"

This expert-led discussion explores how innovative, noninvasive tools are reshaping the lung nodule care continuum.

Moderator Dr. Robert Sussman, Pulmonologist, Summit, NJ, leads a multidisciplinary panel featuring:
Dr. Vijay K. Gunuganti – Medical Oncology & Hematology, Texas Oncology
Dr. Reginald Carl Baptiste – Thoracic Surgeon, Christus Health
Dr. Sai Karan Vamsi Guda – Interventional Pulmonologist, Texas Pulmonary & Critical Care Consultants, PA

Together, they unpack how CyPath® Lung — a noninvasive test utilizing flow cytometry and AI with at-home sample collection — is being integrated into clinical practice to risk-stratify patients, reduce anxiety, and support more informed surgical and treatment decisions.
🎯 Key takeaways from the recording:
✔️ How at-home, noninvasive sample collection supports risk stratification for indeterminate pulmonary nodules
✔️ How flow cytometry and AI detect measurable changes in the lung microenvironment associated with malignancy
✔️ How CyPath® Lung equips pulmonologists, oncologists, and surgeons with additional clinical insight to support earlier diagnosis and improved patient outcomes
Watch the recording now 👉 https://bit.ly/43N4fW1

Address

3300 Nacogdoches Rd Ste 216
San Antonio, TX
78217

Telephone

+12106985334

Website

Alerts

Be the first to know and let us send you an email when bioAffinity Technologies posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category